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Abstract
Treatment with Tositumomab and 131I tositumomab anti-CD20 radioimmunotherapy (Bexxar) yields a non-
radioactive antibody antitumor response (the so-called cold effect) and a radiation response. Numerical parameter
determination by least-squares (LS) fitting was implemented for more accurate parameter estimates in equivalent
biological-effect calculations. Methods: One hundred thirty-two tumors in 37 patients were followed using five
or six SPECT/CT studies per patient, three each (typical) post-tracer (0.2 GBq) and post-therapy (*3 GBq)
injections. The SPECT/CT data were used to calculate position- and time-dependent dose rates and antibody
concentrations for each tumor. CT-defined tumor volumes were used to track tumor volume changes. Combined
biological-effect and cell-clearance models were fit to tumor volume changes. Optimized parameter values
determined using LS fitting were compared to previous fitted values that were determined by matching cal-
culated to measured tumor volume changes using visual assessment. Absorbed dose sensitivity (a) and cold-
effect sensitivity (kp) parameters were the primary fitted parameters, yielding equivalent biological-effect (E)
values. Results: Individual parameter uncertainties were approximately 10% and 30% for a and kp, respectively.
LS versus previously fit parameter values were highly correlated, although the averaged a value decreased and
the averaged kp value increased for the LS fits compared to the previous fits. Correlation of E with 2-month
tumor shrinkage data was similar for the two fitting techniques. The LS fitting yielded improved fit quality and
likely improved parameter estimation.
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Introduction
Biological-effect (E)
1 modeling, where the major functions
affecting therapeutic response are used to calculate total
therapeutic effect, may increase understanding of therapy
effects by quantifying parameters that can be correlated with
patient outcome. In the case of B-cell non-Hodgkins lym-
phoma (NHL) treated with tositumomab and 131I- tositumo-
mab (Bexxar), a significant correlationwith absorbed dose has
not been found.2–4 There is evidence of therapeutic effects
from other factors, such as tumor shrinkage due to non-
radioactive antibody (the so-called cold effect). In our calcu-
lation of E, in addition to absorbed dose, we have included the
absorbed dose rate nonuniformity, the radiation sensitivity,
the sensitivity of the tumor response to the cold effect, and cell
proliferation.
Previously, a wide range of radiation and cold-effect
sensitivities were found, implying the possibility of cate-
gorizing patients for outcome prediction.5 Parameters were
determined for each tumor imaged using SPECT/CT at six
time points, three each over the tracer interval (*8 days) and
the therapy interval (*8 days). Equivalent uniform dose
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(EUD) calculations based on the equivalent biological-effect
model were performed and demonstrated improved correla-
tion of EUD with outcome compared with absorbed dose with
outcome.4 In the present work, the biological-effect model
output was changed to E rather than EUD. EUD is equal to E/
a, where a is the linear radiosensitivity coefficient. This re-
moves an unnecessary influence of the varying patient-specific
radiosensitivity from the biological-effect model output.
The equivalent biological-effect model was combined with
a cell-clearance model to fit relative tumor volume change
data. The equivalent biological-effect model used three pa-
rameters, radiosensitivity (a), cold-effect sensitivity (kp), and
cell proliferation rate (kt). The cell-clearance model used two
parameters, a cell-clearance rate and a cell-clearance delay
for the therapy interval only. The radiosensitivity parameter
and the cell-clearance parameter were significantly corre-
lated because both can directly affect the slope of the change
in tumor volume with time. Since tumor growth for NHL is
typically very slow, cell proliferation has minimal effect over
the *16 days initially used for fitting. Therefore, the cell
doubling rate was held constant in the initial fitting. This
implied that the deviation of the cell proliferation rate from
the chosen value biased the fit parameters, seen mostly in the
effect on the a parameter.
With many freely varying parameters, unrealistic local
minima are frequently found. Model assumptions, random
data error, and unusual patient data presentation can sig-
nificantly affect the model interpretation. A stepwise ap-
proach with fitted parameter constraints was used to help
avoid local minima and maintain a strong correlation of
model parameter interpretation with data.
In the present work, optimized parameter fitting using
least squares (LS) is compared to previously reported
fitting,
5 where the calculated and measured tumor volume
changes were matched by visual assessment by focusing on
the relationship of the radiation and cold-effect sensitivities
to the slope of the tumor volume change (slope-matched or
SM fitting). In SM fitting, an attempt was made to keep all
other model parameters constant. However, it was not pos-
sible to keep the cell-clearance parameters constant and fit the
tumor volume data, thus requiring a change in the cell-
clearance parameters in a minority of fits. LS fitting was
performed with a five-parameter fit (all fitted parameters
varied except proliferation rate) with generous parameter
variation intervals, allowing a more accurate fit and poten-
tially more accurate estimates of the fitted parameters.
Comparison of E calculated by the model to relative tumor
volume change at 2 months post-therapy was used to de-
termine relative success of the fitting techniques.
Materials and Methods
Data collection
One hundred thirty-two tumors in 37 patients were
followed using five or six SPECT/CT studies, three each
(typical) post-tracer (0.2 GBq) and therapy (*3 GBq) in-
jections. The imaging protocol was approved by the Uni-
versity of Michigan Internal Review Board. Each patient
provided written informed consent for the additional im-
aging required. Both tracer and therapy injections used
identical antibody mass, 450mg antibody plus 35mg of
131I-labeled antibody. Patients were imaged on a Siemens
Symbia TruePoint SPECT/CT scanner (Hoffman Estates,
IL) with a six-slice CT capability. The high-energy parallel-
hole collimation was used, with 180o and 30 stops per
head, 40 seconds per stop, body contouring, 20% photo-
peak at 364 keV, two adjacent 6% scatter correction win-
dows, and a 128 · 128 matrix with a pixel size of 4.8mm.
The CT used full rotation, 130 kVp, and 35 mAs. The CT
dataset yielded a 1 · 1 · 2mm (typical) voxel size. Uni-
versity of Michigan software was used for SPECT/CT re-
construction and quantification. Projection data were
reconstructed with ordered subsets expectation maximi-
zation (OSEM) using 35 iterations and six subsets and in-
cluded three-dimensional (3D) depth-dependent detector
response compensation, attenuation correction, and scatter
correction. Partial volume recovery coefficients6 ranged
from 99% to 58% for 100 to 4mL volumes, respectively.
Registered SPECT/CT data were used to deter-
mine voxelized descriptions of tissue densities and activity
concentrations, as described by Dewaraja et al.4 SPECT-
determined activity distributions and Monte Carlo-
calculated 3D dose rate distributions7 were combined with
tumor and rest-of-the-body time-activity curves to yield a
position and time-dependent dose rate distribution and
antibody concentration distribution for each tumor. Tumor
volume contours defined on CT were used to derive the
time dependence of tumor volumes for tracer and therapy
time points. Shown in Figure 1 are example CT images
with tumor contour (Fig. 1A) and SPECT overlay (Fig. 1B).
Tumor time-activity data were fit using a biexponential
function with the two components representing the uptake
and clearance of antibody, respectively. Rest-of-the-body
(whole body minus tumor) time-activity data were fit
FIG. 1. Fused SPECT and CT Images for a Representative Patient. Shown are central slice tumor images for the first therapy
scan for the inguinal region (A) CT with contour, (B) SPECT overlay on CT. Color images available online at www
.liebertpub.com/cbr
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using a monoexponential function representing antibody
clearance.8
Equivalent biological-effect model
The equivalent biological effect, E, is defined at the mini-
mum (time of minimum, tmin in hours) of the voxelized cell
survival fraction S(v,t), averaged over voxels,
E¼ ln [<S(v, tmin) > v ] (1)
Viable cell loss or gain is a function of the biological-
effective therapy, BET, containing three terms representing
radiation effect, proliferation, and cold effect with coeffi-
cients a, kt and kp, respectively.
S(v, t)¼ N(v, t)
N(v, 0)
¼ eBET(v, t) (2)
where N(v,t) is the number of viable cancer cells in the tumor
in voxel v at time t and
BET(v, t)¼ a D(v, t) kt  tþ kp  P(v, t) (3)
The radiation effect and proliferation terms are defined in
the standard terminology.9 D(v,t) is the cumulative dose to
voxel v at time t postinjection. Dose rate effects (from the
quadratic dose response term) represented approximately 1%
at study dose rates and were ignored.5 The proliferation con-
stant can be expressed as an effective doubling time, Tp in days,
Tp¼ ln (2)
24  kt (4)
The cold-effect term is proportional to the antibody con-
centration residence time (in grams of antibody protein times
hour per gram of tumor),
P(v, t)¼ Pinj
Ainj  qV
Z t
0
A(t¢)  ec  t¢  f (v, t¢)dt¢ (5)
where Pinj and Ainj are the quantity of antibody mass and
activity at time of injection, qV is the tumor mass in g,
A(t¢)  ec  t¢ is the decay-corrected activity as a function of time
(time-activity curve), and f(v,t) is the voxelized activity dis-
tribution at time t, which averages over voxels to unity.
Cell-clearance model
If Z(v,t) is the volume of viable tumor cells in voxel v at
time t, then the time dependence of the total tumor volume is
given by,
Z(t)¼+VZ(v, t), (6)
Z(v,t) has two components, the number of inactivated (but
not yet cleared) cells, U(v,t) and the number of viable cells,
N(v,t)
Z(v, t)¼Cz[U(v, t)þN(v, t)], (7)
where Cz is the volume occupied by a cancer cell, and is
assumed to be constant and equivalent for both viable and
inactive cells. We also assume that at t= 0 the tumor is
composed of only viable cells, Z(v,0) =Cz N(v,0). The position
and time dependence of the tumor volume is
Z(v, t)¼Cz N(v, 0)þ
Z t
0
dU(v, t¢)
dt¢
þ kt N(v, t¢)
 
dt¢
  
(8)
where the first term is the number of initial cells and the terms
in the bracket represent viable cell loss due to therapy and cell
gain due to proliferation. The proliferation term is proportional
to the number of viable cells. Cell loss has two components,
loss due to the radiation effect and loss due to the cold effect,
dU(v, t)
dt
¼  kc
Z t
td
e kc(t t
¢)  a  d[D(v, t
¢ td)]
dt¢
N(v, t¢ td)

 dt¢
þ
Z t
0
e kc(t t
¢)  kp  dP(v, t
¢)
dt¢
N(v, t¢)  dt¢

(9)
where the cell-clearance parameter, kc can be expressed as a
clearance half-time, Tc in days,
Tc¼ ln (2)
24  kc (10)
and td is the clearance delay imposed for the observed delay
in cell clearance for the radiation effect, and can be expressed
in days as Td. The terms in the integrand in equation 8 can be
expressed in N(v,t)/N(v,0), which was explicitly calculated
from equations 2 and 3.
Parameter descriptions are given in Table 1. Additional
detail has been previously published.5,10
Table 1. Parameter Descriptions for the Equivalent
Biological Effect and Cell-Clearance Models
Parameter (units) Description
E Equivalent biological effect
S(v,t) Fractional cell survival
at voxel v and time t
N(v,t) Number of viable tumor
cells at voxel v and time t
tmin, hr Time of cell survival minimum
BET Biological-effective therapy
a, Gy- 1 Linear dose–response coefficient
D(v,t), Gy Dose at voxel v and time t
kt, h
- 1 and Tp, d Proliferation rate and effective
cell doubling time
kp, gT/gp/h
a Cold-effect response coefficient
P(v,t), gp-h/gT Antibody concentration residence
time at voxel v and time t
A(t), Bq Tumor activity time t
c, h - 1 Radioactive decay constant
f(v,t) Relative activity distribution
at voxel v and time t
Z(t), mL Tumor volume at time t
Cz, mL Volume per cell
U(v,t) Number of inactive (nonviable)
tumor cells at voxel v and time t
kc, h
- 1 and Tc, d Cell-clearance constant and
cell clearance half-life
td, h and Td, d Cell-clearance delay time
aGram of tumor per gram of antibody protein per hour.
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Voxelized tumor volume
Tumor volumes were defined on CT and registered over
time with deformable registration using center of mass
alignment and radial deformation. Voxels from the initial
scan were tracked in subsequent scans by fixing the number
and relative positions of voxels for all time points. The tumor
time-activity curves at the voxel level followed the curve for
the tumor as a whole. Local discontinuities in the voxel
curves were allowed at times midway between scans. Dose
rates followed the position and time dependence of the ac-
tivity distribution. The time history of the voxelized tumor
dose rates were calculated with a self-absorption term due to
tumor activity and a rest-of-the-body term due to the rest-of-
the-body activity. The self-absorption term was calculated
using the SPECT-derived source term, which was multiplied
by a recovery coefficient, and the tumor time–activity curve.
The rest-of-body tumor dose rates were calculated from the
rest-of-body source term and the rest-of-body time–activity
curve.
The calculated time dependence of the tumor volume
(equation 6) was compared to the six measured CT-defined
volumes. Model parameters were radiosensitivity (a), cold-
effect sensitivity (kp), proliferation rate (kt) from Equation 3,
effective cell-clearance rate (kc) from Equation 9 and 10, cell-
clearance delay for cell inactivation by the radiation effect (td)
from Equation 9, and tumor volume normalization. Model
input data were dose rate and activity distributions. Model
output was the equivalent biological effect (E) from Equation 1.
Tumor volume normalization was a parameter that multi-
plied the tumor volume data. It was used as a fitted pa-
rameter because of the observed increased variability of the
day 0 tumor volumes compared with days 2 and 5 volumes.
By allowing the tumor volume normalization to vary, tumor
volume errors at all times were treated equally. Example
graphs of fitted time-dependent tumor volumes are pre-
sented in Figure 2.
Slope-matched fitting
Slope-matched (SM) fitting was performed by adjusting
the a and kp parameters for optimum agreement between the
slopes of the calculated tumor-volume curve (equation 6)
and the tumor-volume data for the tracer and therapy time
intervals.5 The fitting procedure attempted to hold other
parameters constant, but allowed variations of the cell-
clearance parameters when required to achieve a fit. Varia-
tions of the clearance parameters were used in a minority of
tumor fits and were chosen based on tumor volume data
characteristics. Emphasis was placed on determining the
radiation and nonradioactive antibody sensitivities based on
slopes of the tumor volume change data (i.e., tumor shrink-
age) with the least influence of confounding effects. Tumor
volume data in the tracer time interval was primarily sensi-
tive to the cold-effect parameter, while data post-therapy
injection was primarily sensitive to the radiosensitivity pa-
rameter. Tumor volume data normalization depended on
the volume variations observed for the tracer time interval.
Tumor data showing little or no cold effect used the average of
all three tracer volumes (in 115 of 132 fits). Tumor data with
a large cold effect were normalized to the initial volume only
(9 of 132 fits). For tumor data with large decreases between
the initial volume and following two volumes (ranging from
16% to 48% in 8 of 132 tumor fits), it was not reasonable to
assume the change in tumor volume was due to tumor cell
clearance alone, which appeared to violate model assump-
tions. For these, the second and third data points only were
used for normalization, while the first point was ignored
during the fitting. The cell clearance half-time was 3 days
(Tc, equation 10), unless this assumption was inconsistent with
FIG. 2. Tumor Volume Data and Example Fits. Shown are
measured volumes (dots), tumor–volume fitted curves (solid)
and fractional cell survival (S, dashed) for least-squares (LS)
and slope-matched (SM) fitting. Data and curves are nor-
malized to the tumor volume at time zero for the LS fit. Plots
are shown for an (A) increase in E (Patient 5, Tumor 4); (B)
no change in E (Patient 39, Tumor 3); (C) decrease in E
(Patient 36, Tumor 3) for the LS fit relative to the SM fit,
respectively.
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the tumor volume data. Alternative values used were 1, 1.5,
or 2 days (1, 2, and 9 of 132, respectively). The clearance
delay parameter (td, equation 9) was set based on the time of
the sharp drop in tumor size, assumed to be due to cell
clearance secondary to radiation damage. Clearance delays
were 0, 1.5, or 4 days (17, 112 and 3 of 132, respectively).
Proliferation was held constant at a half-time of Tp= 150 days
(equation 4) to represent the median time to progression for
low-grade NHL.11 While observing the tumor–volume curve
match to data points, parameters kp and a were varied until
the slopes of the tumor–volume curves approximately mat-
ched the data points for the tracer and therapy intervals,
respectively. Fit conditions are summarized in Table 2.
LS fitting
LS fitting allowed more freedom of parameter variation.
Parameters were limited to finite ranges to avoid nonphysi-
cal local minima. Parameter limits were generous (given in
Table 3). Tp was held constant at 500 days, a value consistent
with the progression observed at 2 months for the majority of
tumors in this study. In a first step, fitting was performed
using tumor–volume normalization and kp, keeping other
parameters at nominal values. In a second step, fitting was
performed keeping tumor–volume normalization and kp
fixed and optimizing a, kc, and td within the chosen intervals.
Fitting was performed at least twice per tumor, iteratively for
the first and second steps, using the previous best fit pa-
rameters as initial values. To avoid local minima, multiple
overlapping intervals for td were chosen based on the ob-
served time of rapid tumor volume decrease following the
therapeutic injection. Some tumors required a refitting with
an alternative td interval with the best final fit chosen. A
small overlap between td intervals helped determine the best
fit values without danger of a local minimum trap. The
numbers of tumor fits were 3, 33, 74, and 22 in 4 td intervals
listed in Table 3, respectively.
E value correlations with 2-month shrinkage data were
used to determine relative quality of the fitting procedures
for both SM and LS techniques. The log of the ratio of the
2-month tumor volume to the initial tumor volume was
plotted against E. Complete response at 2 months (i.e., tumor
volume not observed on CT) was plotted using a minimum
volume of 0.25mL.
To illustrate potential errors in fitting with only the first
*16 days of data, example tumor fits were refit using LS
with kt varying (least squares including time term, or LST,
fit) and using the 2-month data. Tumor fits farthest from the
LS shrinkage-versus-E best fit line were chosen for LST fit-
ting. Tumor size normalization was held constant at the
previous LS fit value, leaving five fit parameters (a, kp, kc, td,
and kt). A larger kc interval was allowed to enable the
2-month data to be reliably fit while maintaining a similar fit
quality compared to the LS fit with kt constant described
above.
Results
LS fitting provided an estimate of parameter uncertainty
per fit based on the variability of the data. The one standard
deviation uncertainty was approximately 10% and 30% for a
and kp, respectively. For some tumors, the LS fit resulted in a
significant departure from previous fitting for the alpha pa-
rameter due to the added freedom of the clearance param-
eters. Figure 2A–C show example fits where the resulting
E value increased, stayed approximately the same, or de-
creased, respectively, for the LS fit relative to the SM fit.
LS versus SM parameter results were correlated for indi-
vidual tumor data fits, as illustrated by the square of the
correlation coefficient, R2 = 0.40 for a ( p< 10 - 3, data not
shown) and R2 = 0.66 for kp ( p< 10 - 3, data not shown). Using
results averaged over tumors for each case, R2 = 0.53 for a
( p< 10 - 3, Fig. 3A) and R2 = 0.83 for kp ( p < 10 - 3, Fig. 3B). On
average, the LS a values decreased while the kp values in-
creased compared with the comparable SM fit values. The
shift in the averaged a value was attributed to the greater
variation allowed for the clearance parameters. A shift in a
driven by data in the therapy interval typically caused a shift
in kp in the opposite direction. The E values, averaged over
tumors for each case, were significantly correlated between
fitting techniques (R2= 0.59, p< 10 - 3, Fig. 3C).
Figure 4 presents the relationship between radiosensitivity
and cold-effect sensitivity. The LS results appear to have
increased the level of case clustering in cell sensitivity to
Table 2. Parameter Ranges for Slope-Matched Fitting
Parameter Condition Value (frequency)
Tumor volume normalization Typical First 3 points (115)
Large cold effect First point (9)
Large decrease from points 1 to 2 and 3 Points 2 and 3 (8)
Radiosensitivity a, Gy- 1 Match slope (therapy) Fitted
Cold sensitivity kp, gT/gp/h Match slope (tracer) Fitted
Clearance half-life Tc, d Typical 3 (120)
Alternative values 1 (1)
1.5 (2)
2 (9)
Clearance delay Td, d No delay 0 (17)
Typical 1.5 (112)
Long delay 4 (3)
Effective cell doubling time Tp, d (constant) Mean time to progression 150
Discrete values were chosen to provide adequate fits to tumor volume data, while only the radiosensitivity and cold-effect sensitivity
parameters were continuously varied.
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therapy. Examples of high radiosensitivity and low cold-
effect sensitivity or high cold-effect sensitivity and low ra-
diosensitivity are more apparent. The LS compared to SM fit
results showed a comparable correlation with 2-month
shrinkage data (Fig. 5). The R2 increased from 0.36 ( p= 0.023)
for SM fitting to 0.38 ( p= 0.014) for LS fitting.
A concern is that the observed correlations are mainly
related to high E values due to patients with higher radio-
sensitivity or cold-effect sensitivity. However, when patients
with radiosensitivity greater than 0.5 Gy- 1 or with cold-
effect sensitivity greater than 150 gT/gp/h (gram tumor per
gram protein per hour) were removed, the correlation be-
tween E and 2-month tumor shrinkage was still apparent,
but with reduced R2 values of 0.23 and 0.34 for SM and LS
fitting, respectively.
Two patients each with large positive and large negative
differences between the location on the plot of LS E versus
2-month shrinkage and the line of correlation (see Fig. 5) were
chosen for repeat LS fitting with the 2-month data included
and with kp varying (LST fit). The patients plotted above the
line of correlation represent a larger therapeutic effect than
was predicted from a linear fit to the LS results. The LST
compared with the LS fit resulted in much larger radio-
sensitivities and longer cell-clearance times (Table 4, columns
2–5). The patients plotted below the line of correlation repre-
sent a smaller therapeutic effect than predicted. The LST fit
had increased cell proliferation (decreased cell doubling time,
Table 4, columns 6–7) or decreased cold-effect sensitivity and
reduced cell-clearance time (Table 4, columns 8–9).
Discussion
The equivalent biological effect and cell-clearance models,
as used here, contain parameters representative of the major
therapeutic and cell-clearance effects. All of the parameters
should be considered ‘‘effective’’ parameters as representing
a group of biological response functions. For example, it is
likely that cells inactivated by radiation versus inactivated by
the cold effect have different clearance mechanisms and
therefore different cell-clearance times, as partially re-
presented by the differing time delay to clearance (td). Yet,
for convenience, both processes are represented by the same
cell-clearance (kc) parameter. There is evidence that a syn-
ergistic relationship exists between cell response to tositu-
momab and subsequent radiation.12 While this effect is not
explicitly included in the model, it may be partially re-
presented in the wide variation of radiosensitivity required
to fit the data.
Using a multiparameter model to fit data should be done
cautiously. SM fitting was done to get a visual relationship
between the slope of the tumor shrinkage curve and the tu-
mor volume data, focusing on estimates of the primary
model parameters (radiosensitivity and cold-effect sensitivi-
ty). Historical use of dose response is equivalent to holding
all model parameters constant, so variation of only two pa-
rameters was a small departure. Cell-clearance parameters
were kept constant if doing so resulted in a fit to data. They
were changed only when required to achieve a fit. Allowing
the clearance parameters to vary continuously was explored
as a means of improving the fit quality. Comparison to the
Table 3. Parameter Ranges for Least-Squares Fitting
Parameter
Low
limit
High
limit
Radiosensitivity a, Gy - 1 0.05 2.0
Cold Sensitivity kp, gT/gp/hr 0.7 700
Clearance half-life Tc, d 1 4
Clearance delay Td, d (intervals) 0.15 2.0
1.2 3.8
3.5 4.8
> 4.8
Effective doubling time Tp, d (constant) 500
FIG. 3. SM versus LS Fit Comparison for (A) Radio-
sensitivity, (B) Cold-Effect Sensitivity, and (C) E. Also shown
are the line of equal value and the square of the correlation
coefficient. Parameter values are averaged over tumors for
each patient.
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2-month shrinkage data was used as a test of the need to
vary these parameters and the adequacy of the model to
represent the data.
The proliferation (kt) and cold-effect (kp) parameters played
a relatively minor role in the differences due to fitting tech-
nique. The effective doubling time was changed from 150
days for the SM fitting to 500 days for the LS fitting. While the
approximate mean doubling time (estimated from average
time to progression) was used for the initial SM fitting, most
cases were consistent with the much longer time used for the
LS fitting. This change is equivalent to using the mode rather
than the mean of the distribution. The change in Tp did not
cause a substantial shift in the cold-effect parameter, which
was determined by tumor volumes from the first 5 days post-
tracer injection. The volume normalization and kp were de-
termined together so that the initial tumor volumes could be
used to determine an unbiased normalization while account-
ing for the (mostly) modest tumor response to the antibody
alone. All following LST fits kept the volume normalization
fixed to reduce the number of fit variables.
The strategy of shifting to LS fitting generated some con-
cern that the correlation of the radiosensitivity and cell-
clearance (a and kc) parameters would adversely affect the
estimate of a. A relatively small interval for the clearance
parameter was allowed for this reason. However, the added
flexibility for LS fitting allowed higher quality fits. Improved
performance of the LS fitting was consistently apparent for
both the tumor-specific and patient-specific results. Patient-
specific results showed a higher correlation than tumor-
specific fits, probably because some averaging over multiple
tumors per patient reduced the effects of random fluctuations
in the data. For patients with multiple tumors, variations be-
tween tumor shrinkage data was much less intra-patient
compared to inter-patient. Some testing with larger intervals
of kc for LS fitting was performed, but it was concluded that
any further gains in model performance would be modest at
best. The upper limit placed on Tc was reached in 36 of 132
(27%) of LS fits. The lower limit of Tc was close to a practical
minimum value and was not explored. LST fits that in-
cluded 2-month data and varying proliferation parameter
required an increased range for the clearance parameter to
provide an adequate representation of the data, with re-
duced concern for a correlation between a and kc because of
the additional constraint provided by the 2-month data
point. The improved fit quality of LS fitting compared to
the previous SM fitting was a validation that the effective
cell-clearance time varied between tumors and between
patients.
The LST fits were performed to explore the further pa-
rameter variations resulting from adding additional time
data, which allowed inclusion of kt as a fit parameter. Since
using kt and the 2-month data in fitting would yield almost
perfect agreement between E and the 2-month data, only the
points in furthest disagreement needed to be tested. As in-
dicated by comparing changes for LST versus LS fits, there
are fits that yielded much larger or smaller cell-clearance
times to reproduce the tumor shrinkage data. A larger cell-
FIG. 4. Fitted Sensitivity Parameters Averaged Over Tu-
mors for Each Patient for SM and LS Methods.
FIG. 5. Correlation of E with 2-Month Tumor Shrinkage for
SM Fitting (solid line, R2 = 0.36, p= 0.023) and LS Fitting
(dashed line, R2 = 0.38, p= 0.014).
Table 4. Least-Squares Fit Parameter Comparison Without (LS) and With (LST) ks Varying
and 2-Month Tumor Size Data for the Four Plotted Points in Figure 5 in Most Disagreement
With the E Versus 2-Month Shrinkage Best Fit Line
Plot point (0.92,4.6) Plot point (1.45,4.9) Plot point (0.82,- 0.5) Plot point (2.05,1.3)
Parameter LS LST LS LST LS LST LS LST
a, Gy - 1 0.222 1.60 0.718 1.62 0.05 0.05 0.05 0.05
kp, gT/gp/h 35.0 0.70 35.7 49.3 12.5 19.7 329 192
Tc, d 2.5 8.0 1.0 3.3 2.7 1.0 4.0 1.4
Td, d 2.8 2.8 2.3 2.3 2.0 2.0 3.8 3.8
Tp, d 500 549 500 513 500 188 500 500
E 0.92 5.71 1.45 3.27 0.82 0.42 2.05 1.03
Point coordinates refer to [E,log tumor shrinkage] values plotted in Figure 5.
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clearance time can mask a high radiosensitivity if the anal-
ysis uses data for the first several weeks only. Likewise, ig-
noring variations in tumor cell proliferation can yield
incorrect estimates of therapeutic effect in some cases. LST
fits are expected to yield more accurate estimates of the
sensitivity parameters.
Because proliferation for NHL is typically low, the mini-
mum of the cell survival curve (used to derive E) is similar to
the cell survival at 2 months. Thus, it is reasonable that E
should predict shrinkage at 2 months if the model correctly
represents the observed cell survival during the tracer and
therapy intervals. This relationship holds even when high
responders are removed from the dataset. Variability of cell
sensitivity to therapy is a consistent feature of tumor re-
sponse at both high and low tumor sensitivities. Following
the removal of high-sensitivity cases, the remaining case with
high E value ( > 2) was distinguished from other cases by
significantly higher absorbed dose.
Full parameter variation of the model is not limited by the
quality of the fit to tumor shrinkage data, but by the accuracy
of those data. Validation of the full fit is hampered by the
increased difficulty of obtaining high quality outcome data at
times longer than 2 months, since many patients with re-
current disease go on to other therapies. While a correlation
of the model parameters with tumor size was expected, a
correlation was not found for the LS fit results. At a mini-
mum, LST fit results would be required to test for a corre-
lation of proliferation rate with tumor size.
The usefulness of the model may be judged by correlating
model parameters with pretherapy biomarkers. Optimum
parameter values are obtained with the full fit including the
2-month shrinkage data and a fitted proliferation parameter.
A prediction of the radiosensitivity, cold-effect sensitivity,
and proliferative potential based on biomarkers would allow
an estimate of therapy effect. A prospective study of the
predictability of outcome using biomarkers would be re-
quired. Example biomarkers under study include disease
diagnosis (e.g., follicular lymphoma), p53 for apoptosis or
cell repair potential and Ki67 for proliferative potential.
Prediction of outcome could influence patient enrollment in
dose escalation or radiosensitizer studies or encourage the
use of alternative therapeutic options for some patients.
Conclusion
LS fitting allowed more variation of model parameters
and yielded more accurate fits to the tumor shrinkage data in
the tracer and therapy intervals. Comparisons of LS fitting to
previous SM fitting increased confidence in fitting techniques
and allowed the inclusion of proliferation rate as a fitted
parameter. Three of 37 cases were classified as more radio-
sensitive (a > 0.5 Gy - 1) and 4 of 37 cases as more cold-effect
antibody sensitive (kp > 150 gT/gp/h). E was significantly
correlated with the 2-month tumor shrinkage data, with
likely improvement in parameter estimation from fitting that
included proliferation. Equivalent biological-effect calcula-
tions promise to improve understanding of the disparity of
therapy results from this patient population by segmenting
populations into low or high effective radiosensitivity, cold-
effect sensitivity, and/or proliferative potential categories,
each category potentially benefitting from a different thera-
peutic strategy. Biomarker correlation with effective radio-
sensitivity, effective cold-effect sensitivity, and/or
proliferative potential may yield pretherapy predictions of
therapy outcome, and thus potentially influence the thera-
peutic management of B-cell NHL patients.
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